美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Liminatus Pharma LLC

6.50

-0.9148-12.35%

成交量：6.59萬

成交額：43.10萬

市值：1.73億

市盈率：- -

高：7.79

開：6.00

低：5.70

收：7.41

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Liminatus Pharma LLC

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

6 Centerpointe Drive,#625,LA Palma,California,United States

官網：

- -

郵編：

90623

電話：

- -

傳真：

- -

簡介：

Liminatus Pharma, Inc.是一家特拉華州公司，成立於2022年11月23日。Liminatus是一家臨床前階段的生物製藥公司，開發新型的免疫調節癌症療法。公司候選IBA101，是一種人源化抗CD47單抗。下一代CD47檢查點抑製劑的初步適應症預計為包括非小細胞肺癌在內的晚期實體癌患者。作為一家全球領先的生物製藥公司，該公司的願景是為癌症患者開發一系列廣泛的變革性療法。

董事

名稱

職位

Rohit Nanani

Chairman of the Board

Manish Shah

Director

Nicholas Fernandez

Director

Richard Peretz

Director

股東

名稱

職位

Sumit Mehta

Chief Executive Officer

Lisha Parmar

Chief Financial Officer

Omkar Halady

Vice President

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/LIMN/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LIMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LIMN\",,,,,undefined,":{"symbol":"LIMN","market":"US","secType":"STK","nameCN":"Liminatus Pharma LLC","latestPrice":6.4952,"timestamp":1746550736412,"preClose":7.41,"halted":0,"volume":65864,"delay":0,"floatShares":19874497,"shares":26600000,"eps":0,"marketStatus":"交易中","change":-0.9148,"latestTime":"05-06 13:01:38 EDT","open":6,"high":7.79,"low":5.7,"amount":430996.1866152,"amplitude":0.282051,"askPrice":6.49,"askSize":400,"bidPrice":6.1,"bidSize":20,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1746561600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":7.41,"preHourTrading":{"tag":"盘前","latestPrice":6.82,"preClose":7.41,"latestTime":"09:10 EDT","volume":430,"amount":2969.03992,"timestamp":1746537021595},"postHourTrading":{"tag":"盘后","latestPrice":6.7,"preClose":7.2,"latestTime":"19:56 EDT","volume":2048,"amount":13509.2899,"timestamp":1746489363530},"volumeRatio":0.913112},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LIMN\",,,,,undefined,":{"symbol":"LIMN","floatShares":19874497,"roa":"--","roe":"--","lyrEps":-0.403845,"volumeRatio":0.913112,"shares":26600000,"dividePrice":0,"high":7.79,"amplitude":0.282051,"preClose":7.41,"low":5.7,"week52Low":5.01,"pbRate":"--","week52High":16.44,"institutionHeld":0,"latestPrice":6.4952,"committee":-0.904762,"eps":0,"divideRate":0,"volume":65864,"delay":0,"ttmEps":0,"open":6,"prevYearClose":11.22,"prevWeekClose":8.04,"prevMonthClose":6.43,"prevQuarterClose":9,"fiveDayClose":5.01,"twentyDayClose":9,"sixtyDayClose":11.59},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":570895157,"address":"6 Centerpointe Drive,#625,LA Palma,California,United States","zipCode":"90623"},"stockCompanyDetail":{"stockEarnings":[{"period":"1week","weight":0.4371},{"period":"1month","weight":-0.2},{"period":"3month","weight":-0.3788},{"period":"6month","weight":-0.3514},{"period":"1year","weight":-0.3064},{"period":"ytd","weight":-0.3583}],"compareEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":0.1152},{"period":"3month","weight":-0.0636},{"period":"6month","weight":-0.0466},{"period":"1year","weight":0.1021},{"period":"ytd","weight":-0.0385}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Liminatus Pharma, Inc.是一家特拉華州公司，成立於2022年11月23日。Liminatus是一家臨床前階段的生物製藥公司，開發新型的免疫調節癌症療法。公司候選IBA101，是一種人源化抗CD47單抗。下一代CD47檢查點抑製劑的初步適應症預計為包括非小細胞肺癌在內的晚期實體癌患者。作為一家全球領先的生物製藥公司，該公司的願景是為癌症患者開發一系列廣泛的變革性療法。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.009402},{"month":2,"riseRate":1,"avgChangeRate":0.015297},{"month":3,"riseRate":0.5,"avgChangeRate":-0.065679},{"month":4,"riseRate":0.5,"avgChangeRate":-0.073295},{"month":5,"riseRate":0.5,"avgChangeRate":0.066991},{"month":6,"riseRate":0.5,"avgChangeRate":-0.007302},{"month":7,"riseRate":0.5,"avgChangeRate":-0.009101},{"month":8,"riseRate":0.25,"avgChangeRate":-0.003864},{"month":9,"riseRate":0.75,"avgChangeRate":0.007824},{"month":10,"riseRate":0.75,"avgChangeRate":0.000686},{"month":11,"riseRate":0.5,"avgChangeRate":-0.003101},{"month":12,"riseRate":0.75,"avgChangeRate":0.009144}],"exchange":"NASDAQ","name":"Liminatus Pharma LLC","nameEN":"Liminatus Pharma LLC"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LIMN\",market:\"US\",,,undefined,":{"directors":[{"name":"Rohit Nanani","position":"Chairman of the Board"},{"name":"Manish Shah","position":"Director"},{"name":"Nicholas Fernandez","position":"Director"},{"name":"Richard Peretz","position":"Director"}],"executives":[{"name":"Sumit Mehta","position":"Chief Executive Officer"},{"name":"Lisha Parmar","position":"Chief Financial Officer"},{"name":"Omkar Halady","position":"Vice President"}]},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LIMN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-09-06","symbol":"LIMN","reason":null,"defaultRemindTime":1725629400000,"announcedDate":"2024-09-05","type":"delisting","dateTimestamp":1725595200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LIMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LIMN\",market:\"US\",delay:false,,,undefined,":{}}}